The global molecular quality controls market is projected to expand steadily, driven by the increasing adoption of molecular diagnostic tests, rising demand for precision medicine, and the need for consistent, reliable test results. Molecular quality controls play a critical role in ensuring the accuracy and reliability of diagnostic assays, helping laboratories and clinicians maintain high-quality standards.
As molecular diagnostics become more integrated into routine healthcare, especially in areas such as infectious disease testing, oncology, and genetic testing, the demand for robust quality controls is growing. Advances in technology, along with a push for regulatory compliance and accreditation, are further fueling market growth.
With ongoing developments in molecular assay technology and an increasing emphasis on laboratory efficiency and reliability, the molecular quality controls market is expected to grow steadily through 2035.In 2025, the global molecular quality controls market is estimated to be valued at approximately USD 234.4 Million. By 2035, it is projected to grow to around USD 452.6 Million, reflecting a compound annual growth rate (CAGR) of 6.8%.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 234.4 Million |
| Projected Market Size in 2035 | USD 452.6 Million |
| CAGR (2025 to 2035) | 6.8% |
Explore FMI!
Book a free demo
North America is by far the largest market for molecular quality controls, driven by an advanced healthcare infrastructure, high penetration of sophisticated molecular diagnostic technologies and stringent regulatory requirements. These controls are in demand in the United States and Canada, where the application of molecular diagnostics for infectious disease, cancer, and inherited genetic disorders is progressively growing.
Europe is another important market, with a high focus on laboratory accreditation, with a high penetration of molecular diagnostics, and with favorable government policies. Germany, United Kingdom, and France are driving the introduction of molecular quality controls to deliver accurate and reliable test results over a wide range of clinical applications.
Increase of the healthcare expenditures and awareness regarding the quality assurance in the diagnostics testing mechanisms is bolstering the growth of the regional market. As the regional healthcare infrastructure is getting bigger and better with adoption of advanced technology and advance diagnostics countries such as China, Japan, and India are seeing large growth in demand for molecular quality controls.
Challenges
Regulatory Compliance, High Costs, and Technological Standardization
Molecular quality controls market has to deal with the several challenges arising from regulations The increase in regulatory requirements on the manufacturers by FDA (USA), EMA (Europe) and ISO standards applicable for clinical laboratory quality assurance, is a foremost factor expected to curtail molecular quality controls market.
For this reason, compliance with these regulations necessitates considerable validation, proficiency testing and certification, which increases operational costs for manufacturers and laboratories. Another great hurdle is the large cost of molecular quality control materials, which can be particularly steep in advanced molecular diagnostics like next-generation sequencing (NGS), real-time PCR, and digital PCR.
Furthermore, the process of standardization across various molecular platforms and testing techniques varies, leading to inconsistencies in the application of quality control measures and eventually resulting in increased difficulties in comparison of results across laboratories.
Opportunities
Expansion in Personalized Medicine, AI-Driven Quality Control, and Automation in Molecular Testing
Despite these challenges, despite the trends of personalized medicine, artificial intelligence-based optimization of quality control processes in the laboratory, laboratory automation, etc. Demand for high-precision quality control materials is fueled by the growing uptake of molecular diagnostics, including for cancer screening, infectious disease testing, and genetic analysis.
Molecular testing workflows are being improved through the use of predictive analytics from artificial intelligence and machine learning algorithms to find mistakes, enhance data consistency, etc. Technological advancements in automated sample preparation, high-throughput molecular platforms, and digital quality control tracking are all driving laboratory LU efficiency and minimizing manual errors.
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Compliance with FDA, CLIA, ISO 15189, and CAP guidelines for molecular quality control . |
| Consumer Trends | Demand for NGS quality controls, RT-PCR validation, and viral load quantification standards . |
| Industry Adoption | High use in clinical laboratories, genetic testing, and infectious disease diagnostics . |
| Supply Chain and Sourcing | Dependence on specialized reagents, synthetic nucleic acids, and third-party quality control materials . |
| Market Competition | Dominated by diagnostic reagent manufacturers, clinical reference laboratories, and molecular QC providers . |
| Market Growth Drivers | Growth fueled by rising demand for precision diagnostics, increased clinical trial quality monitoring, and regulatory compliance needs . |
| Sustainability and Environmental Impact | Moderate adoption of biodegradable QC reagents, reduced-lab-waste solutions, and eco-friendly packaging . |
| Integration of Smart Technologies | Early adoption of AI-based lab monitoring, digital QC tracking, and cloud-based molecular data management . |
| Advancements in Molecular QC Tools | Development of NGS reference controls, synthetic DNA/RNA calibrators, and real-time PCR assay standards . |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Stricter AI-driven quality control monitoring, automated regulatory compliance systems, and blockchain-based traceability in molecular testing . |
| Consumer Trends | Growth in AI-assisted molecular quality management, real-time error detection software, and personalized QC solutions for precision medicine . |
| Industry Adoption | Expansion into AI-powered molecular QC platforms, decentralized molecular testing, and home-based diagnostic quality control kits . |
| Supply Chain and Sourcing | Shift toward automated reagent manufacturing, AI-optimized supply chain management, and sustainability-driven QC material sourcing . |
| Market Competition | Entry of AI-driven molecular quality startups, block chain -secured lab compliance firms, and cloud-based quality control tracking solutions . |
| Market Growth Drivers | Accelerated by AI-driven molecular quality analytics, real-time QC data integration, and automated precision QC testing . |
| Sustainability and Environmental Impact | Large-scale shift toward carbon-neutral molecular quality control manufacturing, AI-assisted sustainability compliance, and next-gen green laboratory materials . |
| Integration of Smart Technologies | Expansion into block chain -enabled molecular QC transparency, AI-assisted assay standardization, and real-time molecular error correction platforms . |
| Advancements in Molecular QC Tools | Evolution toward AI-powered QC systems, quantum computing-assisted molecular error detection, and smart QC dashboards for clinical diagnostics . |
Molecular quality controls market in United States is expected to expand due to growing adoption of molecular diagnostic techniques and increasing regulatory requirements for laboratory testing along with demand for quality assurance in clinical diagnostics.
Factors such as expanding personalized medicine, growing next generation sequencing (NGS), and growing use of molecular quality controls in infectious disease testing are driving demand for this market. Moreover, marketing of government support toward laboratory accreditation programs and technological improvement in quality control materials is also accelerating industry growth are expected to accelerate the growth of the industry.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 7.0% |
In the United Kingdom, the Molecular quality controls market is experiencing growth due to increasing adoption of precision medicine and growing demand for proficiency testing in molecular diagnostics, and increased use of quality controls in genetic testing laboratories. Market growth is propelled by the adoption of ISO standards on laboratory quality assurance and the continuous advancement of PCR-based quality control methods.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.6% |
The growth of the Molecular quality controls market in Europe is driven by stringent regulations regarding in-vitro diagnostics (IVDs), increasing demand for quality control materials in the field of infectious disease diagnostics, and expansion of molecular testing in the fields of oncology and reproductive health. Moreover, the market is being boosted by EU initiatives encouraging laboratory QMSs and EQA programs.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union (EU) | 6.8% |
The growth of the Japan molecular quality control market for molecular diagnostic applications is moderate and will continue over the forecast period, due to technological advancements in molecular diagnostics technologies, an increase in automation in clinical laboratories, and an increasing focus on high-throughput sequencing quality control, among others. Market trends are being influenced by an increase in demand for molecular quality controls in the field of rare disease testing and personalized medicine.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.7% |
Molecular Quality Controls market in South Korea is showing promising growth owing to the increasing investments towards molecular diagnostic research, increasing adoption of external quality controls (EQCs) in clinical labs and the government support towards standardized diagnostic protocols. The increase in the number of NGS-based testing and the rising need for multi-analyte molecular controls are contributing to the growth of the market.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.0% |
Molecular quality controls are essential for diagnostic assay accuracy, laboratory instrument calibration, and test performance verification in clinic-based and research settings. The adoption of molecular diagnostics in infectious disease detection, oncology testing, and genetic analysis is on the uptrend, resulting in an increased demand for reliable molecular controls. The market is segmented into Analyte (Single-analyte Controls, Multi-analyte Controls) and Product Type (Independent Controls, Instrument-Specific Controls) segments.
Multi-Analyte Controls Lead Market Demand
With the ability to validate multiple biomarkers or diagnostic targets in a single test, Multi-Analyte Controls contributes the largest share of the market. The use of multi-analyte controls provides a more integrated approach to laboratory automation, allowing for greater efficiency by improving workflow and decreasing variability in both testing procedures as well as molecular diagnostic outcomes.
However, as the number of targets within infectious disease screening, genetic testing, and oncology diagnostics continue to grow, laboratories need to perform high-throughput and cost-effective tests, and demand multi-target controls. These controls are commonly applied in real-time PCR, next-generation sequencing (NGS), and microarray-based assays.
The Single-Analyte Controls segment is also experiencing pulling demand, especially in the area of target oncology diagnostics, biomarker testing, and routine infectious disease screening. Single-analyte controls enable exceptional precision for individual molecular markers, which is critical for specific testing applications.
The growing application of personalized medicine, companion diagnostics, and pathogen-targeted assays in molecular laboratory practice keep single-analyte controls relevant in the quality assurance landscape.
Independent Controls Dominate Market Growth
The Molecular Quality Controls Market is segmented based on Type of Independent Controls, wherein Independent Controls is estimated to remain the dominant segment; most molecular diagnostic assay manufacturers rely on these Independent Controls for external validation of their performance across various platforms, manufacturers, and testing methodologies.
Examples of independent controls used in molecular testing help minimize biases, and promote standardization across laboratories and specimens, and improve comparability across laboratory platforms.
This trend is being driven by growing third-party quality control adoption, as well as increasing regulatory requirements for assay validation, and demands for strong laboratory accredited programs, which make independent controls the assay of choice in clinical and research laboratories around the world.
The Instrument-Specific Controls market is also emerging, especially among diagnostic device manufacturers and laboratories using closed loop platforms. These control materials are specifically formulated to meet the needs of proprietary diagnostic instruments to the exact performance, calibration and quality assurance specifications established by the manufacturers.
The demand for automated molecular diagnostics, point-of-care testing, and multiplexed assay systems continues to be market drivers due in part to the existence of instrument-specific controls in both centralized and decentralized diagnostics.
Increasing demand for accurate diagnosis through molecular quality control in diagnostic testing, regulatory compliance in molecular diagnostics, and technological advancement in quality assurance for infectious and genetic disease testing are the key factors propelling growth for molecular quality controls market. Key factors attributable to the market growth include automation of quality control (QC) through artificial intelligence (AI), standardization of next-generation sequencing (NGS), and rising uptake of external quality assessment (EQA) programs.
In the diagnosis market, companies are prioritizing high-precision diagnostics, regulatory compliance, and laboratory efficiency through AI-enhanced molecular assay validation, automated quality control solutions, and multi-analyte reference materials.
Market Share Analysis by Key Players & Molecular Quality Control Providers
| Company Name | Estimated Market Share (%) |
|---|---|
| Bio-Rad Laboratories, Inc. | 18-22% |
| Thermo Fisher Scientific, Inc. | 12-16% |
| LGC Limited | 10-14% |
| Roche Diagnostics | 8-12% |
| Microbiologics, Inc. | 5-9% |
| Other Molecular Quality Control Providers (combined) | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Bio-Rad Laboratories, Inc. | Develops AI-powered molecular quality control systems, multiplexed reference materials, and real-time PCR assay validation tools . |
| Thermo Fisher Scientific, Inc. | Specializes in AI-assisted NGS quality control, high-sensitivity molecular diagnostics, and external quality assessment programs . |
| LGC Limited | Provides AI-driven assay standardization, genomic quality control materials, and high-throughput molecular proficiency testing solutions . |
| Roche Diagnostics | Focuses on AI-enhanced molecular assay quality monitoring, automated external quality control platforms, and precision medicine quality programs . |
| Microbiologics, Inc. | Offers high-quality synthetic molecular controls, AI-assisted pathogen detection quality systems, and lab proficiency evaluation tools . |
Key Market Insights
Bio-Rad Laboratories, Inc. (18-22%)
Bio-Rad leads the molecular quality controls market, offering AI-driven molecular assay validation, real-time PCR quality controls, and NGS reference standards.
Thermo Fisher Scientific, Inc. (12-16%)
Thermo Fisher specializes in high-sensitivity molecular quality controls, ensuring AI-powered NGS workflow standardization and external quality assurance solutions.
LGC Limited (10-14%)
LGC provides AI-assisted molecular test proficiency programs, optimizing assay reproducibility and regulatory compliance for diagnostics labs.
Roche Diagnostics (8-12%)
Roche focuses on AI-enhanced precision medicine quality control, integrating automated molecular assay monitoring for infectious disease and genetic testing.
Microbiologics, Inc. (5-9%)
Microbiologics develops synthetic molecular controls, ensuring AI-optimized quality assessment for pathogen detection and molecular diagnostic workflows.
Other Key Players (30-40% Combined)
Several molecular diagnostic companies, reference material providers, and clinical laboratory suppliers contribute to next-generation molecular quality control innovations, AI-powered assay standardization, and global regulatory compliance advancements. These include:
The overall market size for the molecular quality controls market was USD 234.4 Million in 2025.
The molecular quality controls market is expected to reach USD 452.6 Million in 2035.
Growth is driven by the increasing adoption of molecular diagnostics, rising prevalence of infectious diseases and cancer, advancements in quality control technologies, and stringent regulatory requirements for diagnostic accuracy.
The top 5 countries driving the development of the molecular quality controls market are the USA, Germany, China, Japan, and the UK.
Independent and Instrument-Specific Molecular Quality Controls are expected to command a significant share over the assessment period.
Portal Hypertension Management Market Trends - Size, Growth & Forecast 2025 to 2035
Pleural Diseases Therapeutics Market – Drug Trends & Future Outlook 2025 to 2035
Nasal Polyposis Treatment Market - Drug Innovations & Demand 2025 to 2035
Next Generation Immunotherapies Market - Innovations & Growth 2025 to 2035
Large Molecule Bioanalytical Testing Services Market - Growth & Demand 2025 to 2035
Laband Syndrome Therapeutics Market Growth - Trends & Future Innovations 2025 to 2035
Molecular Quality Controls Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
